Guggenheim analyst Eddie Hickman reiterated a Buy rating on Tarsus Pharmaceuticals (NASDAQ: TARS).The analyst commented: "We continue to monitor the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE